Sanofi obtained exclusive worldwide rights to two AI-engineered bispecific antibodies (HXN-1002 targeting α4β7/TL1A and HXN-1003 targeting TL1A/IL23) for autoimmune and IBD indications. Earendil received $125M upfront and is eligible for up to $1.72B in milestones plus tiered royalties. Follow-on validation: in January 2026 Sanofi and Earendil signed a separate, broader strategic collaboration (up to $160M upfront/near-term, up to $2.56B total) applying Earendil's AI discovery platform to additional autoimmune/inflammatory programs, reinforcing the platform thesis behind this initial HXN-1002/HXN-1003 license.
Key facts
AnnouncedApr 17, 2025
ClosedApr 17, 2025
Deal value$1.8B
Deal typeLicensing/Option
Therapeutic areaAutoimmune and inflammatory bowel diseases
IndicationsAutoimmune and inflammatory bowel diseases
Key assetsHXN-1002 and HXN-1003
MechanismAI-engineered bispecific antibodies (α4β7/TL1A and TL1A/IL23)